Form 4: Revelation Biosciences CFO Receives Stock Grant
Insider Transaction (Form 4)
Chester Stanley Zygmont Iii, Chief Financial Officer of Revelation Biosciences, Inc., reported multiple transactions in common stock on August 17, 2026.
Summary
- Grant/award: acquired 208,073 Common Stock on August 17, 2026; holds 208,073 after (Direct).
- Bona fide gift: disposed of 208,073 Common Stock on August 17, 2026 (Direct).
- Bona fide gift: acquired 208,073 Common Stock on August 17, 2026; holds 300,136 after (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Chester Stanley Zygmont Iii — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Grant/award | Common Stock | 208,073 | — | — | 208,073 |
| 2026-08-17 | Bona fide gift | Common Stock | 208,073 | — | — | 0 |
| 2026-08-17 | Bona fide gift | Common Stock | 208,073 | — | — | 300,136 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Grant/award (208,073 shares) |
| 2026-08-17 | Bona fide gift (208,073 shares) |
| 2026-08-17 | Bona fide gift (208,073 shares) |
Keywords
insider transaction, Form 4, REVB, REVELATION BIOSCIENCES, INC., neutral, Chester Stanley Zygmont Iii
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.